Andreessen Horowitz unveils $450 mln second bio fund


KKR, Kohlberg Kravis Roberts, healthcare, private equity, Slayback Pharma, pharmaceuticals
Andreessen Horowitz unveiled a $450 million second biotech fund targeting the intersection of biology and engineering, according to a blog post. The firm launched its first bio fund in 2015 with $200 million of capital. As with the first fund, ...
FUNDRAISERS: Don't miss PartnerConnect Southwest on Dec. 4-6 in beautiful Austin, Texas. CLICK HERE FOR DETAILS!

PE Hub Healthcare Wire delivers private equity and M&A healthcare deal activity, fundraising news, people moves, regulatory updates and much more every Thursday. Subscribe now! It’s FREE.

This content is available for Venture Capital subscribers only. Request a free trial to get access for a limited period

Venture Capital

Subscribe Now Request Trial

If you already have an active Venture Capital subscription, please sign in to view this article.

Digital Edition

VCJ_0118-cover

To read a digital copy of our latest magazine

click here